Pulmonary Fibrosis Life Expectancy: What the 3 to 5 Year Figure Means and How Antifibrotics, Oxygen and Rehab Change It

🫁 Few searches feel as heavy as “pulmonary fibrosis life expectancy”. People type it in the evening after a clinic visit, holding a CT report with the words usual interstitial pneumonia on it. The honest answer is that idiopathic pulmonary fibrosis (IPF) is a serious, progressive disease, but the often quoted median survival of 3 to 5 years is an average from older studies, not a countdown for one person. 🔍 Some people decline within two or three years, others stay fairly stable for a decade, and what happens in between depends on age, lung function, how fast it changes, flare-ups and, since 2014, on antifibrotic treatment. This guide explains where the survival numbers come from, which signals really shape the outlook, how pirfenidone and nintedanib slow decline, how to take them with food and handle nausea, sun sensitivity and liver tests, and when oxygen, pulmonary rehabilitation and a transplant referral make sense.
🫁 What an IPF diagnosis actually means
🔬 Idiopathic pulmonary fibrosis is a scarring disease of the lung tissue itself, the thin walls of the air sacs where oxygen passes into the blood. Repeated small injuries to the lining cells are repaired badly: fibroblasts lay down too much collagen, the walls thicken and stiffen, and the lung slowly loses volume. “Idiopathic” means no outside cause was found, so doctors first rule out rheumatoid arthritis, scleroderma, bird or mould exposure, asbestos and drug-related lung injury.
📊 Where the “3 to 5 years” figure comes from
📖 The figure comes from cohorts of patients diagnosed mainly in the 1990s and 2000s, before any drug was shown to slow the disease. A median is the point at which half of a group has died and half is still alive, so by definition many people in those studies lived well beyond five years.
📈 Today the picture is shifting. Earlier diagnosis on CT, antifibrotic tablets, better management of other illnesses and transplant programmes have all moved the curve, and registry data from treated patients suggest longer survival than the old median, although no one can yet give a reliable new single number. Treat the old figure as a reason to act early, not as a forecast for you.
🔀 Why the average misleads: three common courses
🧭 Lung specialists describe a few typical patterns, and the same diagnosis can follow any of them. The pattern often becomes clear only after 6 to 12 months of repeated breathing tests, which is why the first year of follow-up matters so much.
🧭 What shapes the outlook for one person
📋 No single test predicts survival, but several signals together give a fair picture. The speed of change usually tells more than the starting value: a person with moderate scarring that is stable can do better than someone with milder disease that is falling quickly.
🔢 The GAP index: a simple staging score
🧮 Because IPF has no official cancer-style stages, many clinics use the GAP index, built from Gender, Age and two Physiology tests. It sorts patients into three stages with different risk, and it can be recalculated as numbers change. It was derived from patients treated before antifibrotics, so treated patients today tend to do better than the stage averages.
| 📋 Item | 0 points | 1 point | 2 points |
|---|---|---|---|
| Sex | Female | Male | — |
| Age | 60 or under | 61 to 65 | over 65 |
| FVC, % predicted | over 75 | 50 to 75 | under 50 |
| DLCO, % predicted | over 55 | 36 to 55 | 35 or under (3 points if the test cannot be done) |
📌 A total of 0 to 3 points is stage I, 4 to 5 is stage II, and 6 to 8 is stage III. In the original study, the risk of dying within a year rose from roughly 6% in stage I to about 16% in stage II and close to 40% in stage III. These are group figures from an untreated era; your own doctor will read them together with how your tests are moving.
📉 Tracking decline: FVC, DLCO and the walk test
📏 Forced vital capacity (FVC) is the total volume of air you can blow out after a full breath; DLCO measures how well gas crosses into the blood. Both are repeated every 3 to 6 months. A relative fall in FVC of 10% or more within a year is one of the strongest warning signs, and a fall of 5 to 10% also matters if breathlessness or CT changes go with it.
⚡ Acute exacerbations: the biggest single risk
🚨 An acute exacerbation is a sudden worsening of breathlessness over days to a few weeks, with new shadows on the CT on top of the old scarring, not explained by heart failure or fluid. It can strike at any stage, and it is one of the main causes of death in IPF: in many hospital series a large share of people admitted with one, often around half, do not survive the stay.
🏥 Treatment is in hospital: oxygen, a search for infection, and often high-dose steroids such as prednisolone, an approach based on limited evidence and judged case by case. Steroid tablets like Predniheal (Prednisolone) are not a long-term treatment for stable IPF and should only be used when a specialist prescribes them. Antifibrotics appear to reduce the chance of an exacerbation, which is one more reason to stay on them.
💊 What antifibrotics can and cannot do
🛡️ Two drugs are approved worldwide for IPF: pirfenidone and nintedanib. A third oral option, nerandomilast, gained US approval in 2025. In large trials, both pirfenidone and nintedanib cut the yearly loss of lung volume roughly in half compared with placebo. Pooled trial data and patient registries also point to fewer deaths and fewer hospital admissions, though the trials were not built to prove a survival gain on their own.
Slow the fall in FVC, reduce risk of large drops, likely reduce exacerbations
Reverse scars, cure the disease, or make breathlessness disappear
You cannot feel them working; you see it only in test results over time
📋 Pirfenidone: dosing and the two-week build-up
🧪 Pirfenidone blocks scar-promoting signals such as TGF-beta and reduces fibroblast growth. It is sold as Esbriet and as generics including Pirfenex (Pirfenidone). The dose is raised slowly over two weeks to let the stomach adapt, and every dose is taken with food.
💊 Nintedanib: twice daily, watch the bowels
🧬 Nintedanib (Ofev) blocks several growth factor receptors that drive fibroblasts. The usual dose is 150 mg twice a day, about 12 hours apart, with food, and it can be lowered to 100 mg twice a day if side effects are hard to live with.
🚽 Diarrhoea is the main side effect and affects most people at some point, usually mild and manageable with fluids and loperamide started at the first loose stool. Nausea, loss of appetite, weight loss and raised liver enzymes also occur. Nintedanib may increase bleeding risk, so people on full-dose blood thinners need careful review, and it can harm an unborn baby, so women who could become pregnant need reliable contraception.
⚖️ Pirfenidone and nintedanib side by side
| 🔍 Feature | 💊 Pirfenidone | 💊 Nintedanib |
|---|---|---|
| Doses per day | 3, with meals | 2, with food |
| Start | 2-week build-up | Full dose from day 1 |
| Effect on FVC decline | About half | About half |
| Main side effects | Nausea, poor appetite, sun rash, tiredness | Diarrhoea, nausea, weight loss |
| Liver tests | Needed | Needed |
| Special cautions | Sunlight, smoking lowers levels, fluvoxamine | Bleeding risk, pregnancy, recent bowel surgery |
| Beyond IPF | Used off-label in some fibrosing diseases | Approved for progressive pulmonary fibrosis |
🌳 Choosing between the two
🤔 Because their benefit on lung function is similar, the choice usually comes down to which side effects a person can live with, other illnesses and the medicines already taken. If one drug is not tolerated, switching to the other is common and sensible; giving up on antifibrotics after one bad experience is not.
🍽️ Taking pirfenidone with food and handling nausea
🤢 Nausea, indigestion and loss of appetite are the commonest reasons people stop pirfenidone. Taking each dose in the middle of a proper meal, not with a biscuit, lowers the peak level in the blood and reduces both nausea and dizziness.
💊 A prescriber may add an acid-lowering tablet such as Pepcid (Famotidine) for indigestion, or an anti-sickness medicine such as Zofran (Ondansetron) for the first weeks. Small, frequent, protein-rich meals help keep weight up, which matters because weight loss in IPF is itself linked with a worse outlook.
☀️ Sun sensitivity on pirfenidone
🌞 Pirfenidone makes the skin react to ultraviolet light, causing redness, itching or a burn-like rash after short exposure. This is a real and common reaction, and it can appear even on cloudy days or through a car window.
🧴 Sun protection routine on pirfenidone:
🔹 High-factor sunscreen (SPF 50) that blocks UVA and UVB, reapplied every 2 hours outdoors.
🔹 Wide-brimmed hat, long sleeves, sunglasses; avoid midday sun and sunbeds.
🔹 Ask before starting antibiotics such as doxycycline or other medicines that also raise sun sensitivity.
🔹 Report any rash early; a widespread or blistering rash needs prompt medical review.
🧪 Liver tests: the monitoring schedule
🩸 Both antifibrotics can raise liver enzymes, usually without symptoms and usually reversible when the dose is lowered or paused. Blood tests are therefore planned before the first dose and repeated regularly, most often in the first months.
⚠️ Interactions to check before starting
📝 Pirfenidone is cleared mainly by the liver enzyme CYP1A2, and nintedanib by a transport pump in the gut. Bring a full list of tablets, supplements and herbal products to the clinic, including anything bought without a prescription.
| 🚫 Substance | 💊 Drug | 📝 What happens |
|---|---|---|
| Fluvoxamine | Pirfenidone | Strongly raises levels; should not be combined |
| Ciprofloxacin | Pirfenidone | Raises levels; dose often reduced during the course |
| Smoking | Pirfenidone | Speeds breakdown, lowering levels by around half |
| Grapefruit juice | Pirfenidone | Can raise levels; best avoided |
| Ketoconazole, erythromycin | Nintedanib | Raise levels and side effects |
| Rifampicin, carbamazepine, St John wort | Nintedanib | Lower levels and may reduce benefit |
| Full-dose blood thinners | Nintedanib | Higher bleeding risk; needs close review |
🚫 Treatments that are no longer recommended
📜 IPF used to be treated as an inflammatory disease, and older articles still suggest steroids or immune suppressants. Trials showed that some of these made things worse. The combination of prednisone, azathioprine and N-acetylcysteine led to more deaths and hospital admissions than placebo; warfarin given only for IPF also increased deaths, and ambrisentan was stopped early for harm. N-acetylcysteine on its own did not slow decline.
💨 Oxygen: when it helps and what it changes
🧯 Oxygen does not slow scarring, but it protects the heart and brain from low oxygen and makes activity possible. Long-term oxygen is usually started when resting oxygen saturation falls to about 88% or lower, and ambulatory oxygen is often given earlier for people whose levels drop sharply on walking.
🔥 Never smoke or allow open flames near oxygen equipment. Many people avoid oxygen out of embarrassment and lose fitness as a result; using it during exercise is what keeps the legs strong enough for everyday life.
🏃 Pulmonary rehabilitation
💪 Pulmonary rehabilitation is a supervised programme of exercise, breathing techniques and education, usually two sessions a week for 6 to 12 weeks. In IPF it improves walking distance, breathlessness and quality of life, with the biggest gains in people who start early rather than when already on oxygen at rest.
Walk test, oxygen check, goals
Walking or cycling, light weights, pacing
Longer sessions, energy saving, breathing control
Home plan, 5 days a week, repeat yearly
🔥 Reflux, pulmonary hypertension and other conditions
🩺 People with IPF often carry other illnesses that worsen breathlessness and shorten life if missed. Treating these does not touch the scarring, but it often makes the most noticeable difference in how a person feels.
📖 More on high lung artery pressure in pulmonary arterial hypertension and its treatment. People who also have emphysema or airflow limitation can read chronic obstructive lung diseases.
🚭 Smoking, vaccines and chest infections
🚬 Stopping smoking is the one lifestyle step with a direct link to treatment: smoking lowers pirfenidone levels in the blood and raises the risk of lung cancer, which is already higher in IPF. Medicines such as Chantix (Varenicline) or Zyban (Bupropion) double the chance of quitting compared with willpower alone; see smoking cessation aids explained.
💉 Chest infections are a common trigger of exacerbations. Yearly flu vaccine, pneumococcal vaccine, COVID-19 boosters and, for older adults, an RSV vaccine are all recommended unless a doctor advises otherwise. How doctors judge chest infection severity is explained in pneumonia or bronchitis: severity score and when to go in.
🩺 Lung transplant: refer early, decide later
🏥 A lung transplant is the only treatment that replaces the scarred lung. It is a major operation with lifelong immune-suppressing medicines and real risks, and median survival after lung transplant is roughly 5 to 7 years across all diagnoses, with many living much longer. Because the assessment takes months and IPF can change quickly, guidelines advise referral soon after diagnosis in suitable patients, long before the lungs are at their worst.
🕊️ Palliative care and planning ahead
🤝 Palliative care is not the same as giving up treatment. It works alongside antifibrotics from the time symptoms become a burden, focusing on breathlessness, cough, anxiety, sleep and support for the family.
📝 Questions worth asking your team in the first year:
🔹 How fast are my numbers changing, and which course do you think I am on?
🔹 Am I a transplant candidate, now or later?
🔹 What should I do and whom should I call if my breathing gets suddenly worse?
🔹 Can I be referred to pulmonary rehabilitation and a palliative care team now?
🗿 Myths about pulmonary fibrosis survival
🚨 When to see a doctor urgently
⛔ Get same-day medical help if:
🔹 Breathlessness gets clearly worse over a few days, or you cannot do what you managed last week.
🔹 You have fever, chest pain, coughing up blood, or oxygen readings lower than your usual range.
🔹 Your skin or eyes turn yellow, urine is dark, or you have pain under the right ribs while on an antifibrotic.
🔹 Diarrhoea or vomiting stops you keeping fluids down, or you lose weight steadily.
🔹 Severe breathlessness at rest, blue lips or confusion: call emergency services now.
❓ Frequently asked questions
What is the life expectancy with pulmonary fibrosis?
For idiopathic pulmonary fibrosis, older studies found a median survival of 3 to 5 years from diagnosis. It varies widely: some decline fast, others stay stable for many years, and treatment has improved the outlook.
Can you live 10 years with IPF?
Yes, some people do, especially when diagnosed early with good lung function and a slow course. It is not the most common outcome, so regular tests guide planning.
Does pirfenidone extend life?
It slows the loss of lung function by about half. Pooled trial data and registries suggest fewer deaths, though trials were not designed to prove a survival gain alone.
Is pirfenidone or nintedanib better?
Their effect on lung function is similar. The choice depends on side effects, other illnesses and medicines; switching is common if one is not tolerated.
Why must pirfenidone be taken with food?
Food lowers the peak level in the blood, which reduces nausea and dizziness. Take each dose during a full meal, three times a day.
How do I avoid a sun rash on pirfenidone?
Use SPF 50 sunscreen, cover up, wear a hat and avoid midday sun and sunbeds. Report any rash early so the dose can be adjusted.
How often are liver tests needed on antifibrotics?
For pirfenidone, before starting, monthly for 6 months, then every 3 months. For nintedanib, usually monthly for 3 months, then every 3 months.
When is oxygen needed in IPF?
Long-term oxygen is usually started when resting saturation is about 88% or lower. Portable oxygen may be used earlier if levels drop on walking.
When should I be referred for a lung transplant?
Guidelines advise referral soon after diagnosis in people who may be suitable, because assessment takes time and IPF can change quickly.
What is an acute exacerbation of IPF?
A sudden worsening of breathing over days to weeks with new changes on CT. It is serious, often needs hospital care, and should never be waited out at home.
📑 Sources and editorial
- 📘 International clinical practice guidelines on the diagnosis and treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis
- 🔬 Phase 3 placebo-controlled trials of pirfenidone and nintedanib, and pooled analyses of their outcomes
- 📊 Cohort studies on survival in IPF and the development of the GAP staging index
- 💊 Prescribing information for pirfenidone and nintedanib, including titration, liver monitoring and interactions
- ⚠️ Randomised trials of prednisone, azathioprine and N-acetylcysteine, warfarin and ambrisentan in IPF
- 💨 Studies of ambulatory oxygen and pulmonary rehabilitation in interstitial lung disease
- 🩺 Consensus documents on selection of lung transplant candidates
- 📖 Related reading: pulmonary arterial hypertension, chronic obstructive lung diseases, smoking cessation aids, pneumonia or bronchitis, spotting a flare-up early
- 🛒 Related products: Pirfenex (Pirfenidone), Prilosec (Omeprazole), Nexium (Esomeprazole), Pepcid (Famotidine), Zofran (Ondansetron), Chantix (Varenicline), Zyban (Bupropion), Predniheal (Prednisolone)
- 🩺 RXshop Editorial Team — reviewed by Emily Chen, MD — Internal Medicine
Medical Disclaimer: The information in this article is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek guidance from a qualified healthcare provider with any questions you may have regarding a medical condition, and before starting, stopping or changing any medication.